Cat. No.: HY-19655

Cethromycin

Name: Cethromycin
Brand: MedChemExpress
SKU: HY-19655
Price: 717.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: ABT-773; Abbott-195773; A-195773)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Cethromycin (ABT-773; Abbott-195773) is an orally effective ketolide antibiotic with broad-spectrum antibacterial activity. Cethromycin binds to domains II/V of the 23S rRNA of the 50S subunit, inhibiting bacterial protein synthesis. Cethromycin can accumulate in lung tissue, alveolar macrophages, epithelial lining fluid, and human polymorphonuclear leukocytes. Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Mycoplasma pneumoniae. Cethromycin exhibits significant intracellular and pulmonary enrichment and anti-inflammatory effects against mycoplasma pneumonia in mouse models, improving airway obstruction and airway hyperresponsiveness. Cethromycin disrupts the apicoplast and reduces liver-stage parasite burden during the liver stage of Plasmodium berghei. Cethromycin can be used in research related to pneumonia, Staphylococcus aureus infection, gonorrhea, and malaria.

For research use only. We do not sell to patients.

Purity : 96.19%
CAS No.: 205110-48-1
Formula: C₄₂H₅₉N₃O₁₀
Molecular Weight:765.93

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cethromycin Chemical Structure

CAS No.: 205110-48-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Parmacokinetics
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Antibiotic Isoforms :

All Parasite Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

In Vitro

Bacterial InfectionApoptosisParasitic InfectionInnate ImmunityCytokines & Chemokines

Bacterial Infection

Cethromycin exhibits potent in vitro activity against a variety of respiratory pathogens, including Streptococcus pneumoniae (MIC₉₀ 0.004 to 0.25 µg/mL), Chlamydia pneumoniae (MIC₉₀ 0.015 µg/mL), and Mycoplasma pneumoniae (MIC₉₀ ≤ 0.001 µg/mL)^[1].
Cethromycin exhibits significant in vitro activity against Neisseria gonorrhoeae^[1].
Cethromycin exhibits potent in vitro activity against Borrelia burgdorferi, with MIC₉₀/MBC₉₀ of 0.0019/0.125 µg/mL^[1].
Cethromycin (4-16 × MIC) selected resistant mutants at a significantly lower frequency than erythromycin in S. pneumoniae, S. aureus , and S. pyogenes ^[1].
Cethromycin resistance is associated with specific erm genes and the MLS_B phenotype in S. aureus, where ermA MRSA and ermB/ermC MSSA show higher resistance rates, and the cMLS_B phenotype exhibits higher resistance than iMLS_B in both MRSA and MSSA^[7].
Cethromycin (20 µM; 48 h) disrupts plastid development in the liver stage of P. berghei in Hepa-1-6 hepatocytes, resulting in parasites with a single malformed plastid^[8].

Apoptosis

Parasitic Infection

Cethromycin (20 μM; 42 h) inhibits P. berghei liver-stage parasite growth in Hepa1-6 cells^[3].

Innate Immunity

Cethromycin (10 μg/mL; 3 h) was extensively taken up by human PMNs and did not reach saturation during the incubation period, with an I/E ratio exceeding 500^[4].
Cethromycin (10 μg/mL; 3 h) uptake in THP-1 promonocytes is saturable and reaches a plateau within 60 min^[4].

Innate Immunity

Cytokines & Chemokines

Cethromycin (10 μg/mL; 1 h) was rapidly released from preloaded human PMNs, with approximately 90% effluxed within the first hour of incubation in substance-free medium^[4].
Cethromycin (10 μg/mL; 3 h) was released in large amounts from preloaded THP-1 promonocytes, with approximately 90% excreted within the first 30 min^[4].

Parasitic Infection

Cethromycin (72-144 h) exhibits delayed lethal activity against the blood stages of P. falciparum 3D7^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[8]

Cell Line:

Hepa-1-6 hepatocytes
Concentration:

20 µM
Incubation Time:

48 h
Result:

Resulted in parasites with predominately no observed apicoplasts.
Noted that parasites had single dysmorphic apicoplasts.
Indicated almost normal parasite development nearly indistinguishable from control activity.

Parmacokinetics

Species	Dose	Route	MRT	CL	T_1/2	AUC	C_max	T_max
Mice^[10]	25 mg/kg	p.o.	5.5 h	0.0420 L/h	3.1 h	592.5 mg·h/L	/	/
Mice^[10]	50 mg/kg	p.o.	18.2 h	0.0160 L/h	13.5 h	3070 mg·h/L	/	/
Mice^[10]	100 mg/kg	p.o.	25 h	0.0094 L/h	17.6 h	10600 mg·h/L	/	/
Mice^[10]	200 mg/kg	p.o.	52.8 h	0.0067 L/h	37.2 h	29800 mg·h/L	/	/
Mice^[6]	12.5 mg/kg	p.o.	/	/	5.4 h	14.4 μg·h/mL	0.86 μg/mL	2.0 h
Mice^[6]	25 mg/kg	p.o.	/	/	6.7 h	40.7 μg·h/mL	1.77 μg/mL	2.2 h
Mice^[6]	50 mg/kg	p.o.	/	/	15.9 h	130.3 μg·h/mL	3.63 μg/mL	2.6 h
Mice^[6]	100 mg/kg	p.o.	/	/	38.1 h	474.8 μg·h/mL	7.40 μg/mL	2.8 h
Mice^[6]	200 mg/kg	p.o.	/	/	67.7 h	1,520.0 μg·h/mL	14.59 μg/mL	2.2 h

In Vivo

Parasitic InfectionInnate ImmunityCytokines & ChemokinesOxidative StressBacterial InfectionImmune Tolerance & Immunosuppression

Parasitic Infection

Innate Immunity

Cytokines & Chemokines

Oxidative Stress

Cethromycin (12-50 mg/kg; oral; single administration) reduced P. berghei liver-stage parasite burden at a single oral dose of 50 mg/kg, achieving greater than 99% inhibition when combined with 15 mg/kg Primaquine (HY-12651A)^[3].

Bacterial Infection

Cethromycin (0.1-800 mg/kg/day; oral; once to four times daily) demonstrated significant bactericidal activity against both macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae in a neutropenic mouse pneumonia model, and improved survival^[6].

Parasitic Infection

Cethromycin (15-120 mg/kg; oral; 0-3 doses) exhibits potent causal prophylactic activity and curative effects against the liver stage of P. berghei malaria^[8].
Cethromycin (60 mg/kg; oral; daily; 7 days) exhibits curative efficacy in a blood-stage malaria model in mice with high parasitemia^[8].

Bacterial Infection

Cytokines & Chemokines

Immune Tolerance & Immunosuppression

Cethromycin (25 mg/kg; subcutaneous injection; once daily; 10 days) significantly reduced M. pneumoniae culture titers, lung inflammation, BAL cytokine and chemokine concentrations, and disease severity defined by airway obstruction and airway hyperresponsiveness in a mouse model of M. pneumoniae pneumonia^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (6 weeks old, 20-22 g, female)^[3]
Dosage:

12 mg/kg ; 50 mg/kg
Administration:

p.o.; single dose
Result:

Inhibited parasite load by 16% at 12 mg/kg.
Reduced parasite load by 60% at 50 mg/kg.
Achieved greater than 99% inhibition when combined with primaquine at 15 mg/kg.
Resulted in a 4-fold drop in relative fluorescent units compared to Primaquine alone.

Animal Model:

BALB/c (female, 6-7 weeks old)^[8]
Dosage:

15 mg/kg (single dose on day 1); 30 mg/kg (single dose on day 1); 45 mg/kg (single dose on day 0); 45 mg/kg (single dose on day 1); 60 mg/kg (single dose on day 0); 60 mg/kg (single dose on day 1); 120 mg/kg (single dose on day 1); 20 mg/kg (three separate doses on days -1, 0, and 1); 120 mg/kg (doses on days 0 and 1)
Administration:

p.o.; single dose or multiple doses
Result:

Resulted in 1/3 mice patent with an average day to patency of 8 at 45 mg/kg dosed on day 0.
Resulted in 0/3 mice patent at 60 mg/kg dosed on day 0.
Resulted in 5/12 patent mice with an average day to patency of 8 at 15 mg/kg dosed on day 1.
Resulted in 1/9 patent mice with an average day to patency of 10 at 30 mg/kg dosed on day 1.
Resulted in 0/3 patent mice with delayed patency at 45 mg/kg dosed on day 1.
Resulted in 1/9 patent mice with patency delayed to 13 days at 60 mg/kg dosed on day 1.
Resulted in 0/3 patent mice at 120 mg/kg dosed on day 1.
Resulted in 0/3 patent mice when administered at 20 mg/kg on days -1, 0, and 1.
Resulted in 0/3 patent mice when administered at 120 mg/kg on days 0 and 1.
Resulted in 0/9 patent mice treated with a single oral 60 mg/kg dose 24 hours after sporozoite injection in a separate 3,000 sporozoite tail vein injection model.

Animal Model:

BALB/cj (female, at least 6 weeks old, approximately 20 g)^[8]
Dosage:

60 mg/kg
Administration:

p.o.; daily for 6 or 7 days
Result:

Resulted in partial cure (2/3 mice) with 6 days of treatment.
Resulted in cure of all mice with 7 days of treatment.

Animal Model:

BALB/c (female, 2-month-old)^[9]
Dosage:

25 mg/kg
Administration:

s.c.; once daily; 10 days
Result:

Reduced M. pneumoniae culture titers significantly on days 7 and 10.
Reduced histopathologic score significantly on days 4, 7, and 10.
Reduced 7 of 10 BAL cytokines measured (TNF-α, IFN-γ, IL-1β, IL-8, IL-12, MCP-1, and MIP-1α) significantly on day 4.
Reduced airway obstruction (baseline P_enh) significantly on days 4 and 10.
Reduced airway hyperreactivity (post-methacholine P_enh) significantly on day 4.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 205110-48-1
Appearance Solid
Molecular Weight 765.93
Formula C₄₂H₅₉N₃O₁₀
Color White to off-white
SMILES

O[C@H]1[C@@](O[C@@H]([C@@](OC/C=C\C2=CC(C=CC=C3)=C3N=C2)(C)C[C@@H](C)C4=O)[C@@H](C)C([C@@H](C)C(O[C@H](CC)[C@](OC(N5)=O)(C)[C@@]5([H])[C@H]4C)=O)=O)([H])O[C@H](C)C[C@@H]1N(C)C
Synonyms

ABT-773; Abbott-195773; A-195773
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

BMC Microbiol

The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin. [Abstract]

2023 Apr 20;23(1):109. PMID: 37081393
Research Square Print

December 5th, 2022.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (130.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3056 mL

6.5280 mL

13.0560 mL

5 mM

0.2611 mL

1.3056 mL

2.6112 mL

10 mM

0.1306 mL

0.6528 mL

1.3056 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (306 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hammerschlag MR, et al. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert opinion on investigational drugs. 2008 Mar;17(3):387-400.

[2]. Pavlović D, et al. Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity. ACS medicinal chemistry letters. 2011 May 12;2(5):331-6.

[3]. Sullivan DJ, et al. Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity. PLoS One. 2015 May 7;10(5):e0125593.

[4]. Bosnar M, et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrobial agents and chemotherapy. 2005 Jun;49(6):2372-7.

[5]. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis. 2005 Apr;18(2):125-31.

[6]. Kim MK, et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrobial agents and chemotherapy. 2002 Oct;46(10):3185-92.

[7]. Hu Y, et al. The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin. BMC microbiology. 2023 Apr 20;23(1):109. [Content Brief]

[8]. Kennedy G, et al. Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of Plasmodium berghei liver stages. Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0021525.

[9]. Ríos AM, et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrobial agents and chemotherapy. 2004 Aug;48(8):2897-904.

[10]. Xuan D, et al. Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. J Pharm Pharmacol. 2002 Jan;54(1):71-5.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3056 mL	6.5280 mL	13.0560 mL	32.6401 mL
	5 mM	0.2611 mL	1.3056 mL	2.6112 mL	6.5280 mL
	10 mM	0.1306 mL	0.6528 mL	1.3056 mL	3.2640 mL
	15 mM	0.0870 mL	0.4352 mL	0.8704 mL	2.1760 mL
	20 mM	0.0653 mL	0.3264 mL	0.6528 mL	1.6320 mL
	25 mM	0.0522 mL	0.2611 mL	0.5222 mL	1.3056 mL
	30 mM	0.0435 mL	0.2176 mL	0.4352 mL	1.0880 mL
	40 mM	0.0326 mL	0.1632 mL	0.3264 mL	0.8160 mL
	50 mM	0.0261 mL	0.1306 mL	0.2611 mL	0.6528 mL
	60 mM	0.0218 mL	0.1088 mL	0.2176 mL	0.5440 mL
	80 mM	0.0163 mL	0.0816 mL	0.1632 mL	0.4080 mL
	100 mM	0.0131 mL	0.0653 mL	0.1306 mL	0.3264 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cethromycin

Publications Citing Use of MedChemExpress (MCE) Cethromycin

All Antibiotic Isoforms

All Parasite Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms